Cayman Chemical, a global supplier of high-quality lipids for LNPs, has partnered with Curapath, a company involved in the design, development, and custom manufacturing of polymer and lipid-based drug delivery systems, offering materials in both R&D and GMP quality.

Through this partnership, Cayman will offer Curapath's proprietary polysarcosine (pSar) and polyaminoacid-based shielding lipids for nanoformulation through its extensive catalogue of lipids for LNPs and global network of distributors. Other high-quality polymers such as poly(lysine) and poly(glutamic acid) will also become readily available as well as cationic polymers optimized for gene transfection and delivery.

Developed and manufactured at Curapath's headquarters in Valencia, Spain, Curapath's pSar lipids are synthetic biocompatible polymers that provide a non-toxic, non-immunogenic, and biodegradable alternative to PEGylated lipids with comparable efficacy in LNP formulations.

PEGylated lipids have traditionally been used to shield LNPs from immune detection but concerns about PEG-related immunogenicity and adverse reactions are prompting researchers to seek safer alternatives. Curapath's pSar shielding lipids address these challenges, providing researchers a safe and effective alternative to PEGylated lipids in LNPs.

Cayman brings together expertise in lipid chemistry, synthesis, and analysis to provide researchers with an extensive portfolio of lipids for LNP formulation. Partnering with innovators like Curapath strengthens Cayman's product portfolio and positions the company to provide cutting-edge solutions for LNP researchers, the company stated.

“At Curapath, we're proud to offer next-generation shielding lipids that address the growing need for safer, PEG-free alternatives in LNP formulation. This partnership with Cayman Chemical enables broader access to Curapath's proprietary polymers, empowering researchers worldwide to develop more effective and biocompatible therapies,” it said.